Condition
Real World Study clinical trials and research
As of November 12, 2026, Find a Trial lists 7 Real World Study clinical trials that are recruiting, at sites in 3 countries (most in China (5), Turkey (Türkiye) (1), Netherlands (1)). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 7Clinical trials
- 3Countries
Newest Real World Study clinical trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Real-world use of LC-OCT to help diagnose basal cell carcinoma | — | Maastricht, Limburg | Recruiting | Mar 30, 2026 |
| Iruplinalkib for ALK-positive advanced lung adenocarcinoma after lorlatinib | — | Shenzhen, Guangdong | Recruiting | Jan 29, 2026 |
| Real-world first-line atezolizumab for stage IV NSCLC with PD-L1 ≥50% in Türkiye | — | Adana and 24 other locations | Recruiting | Dec 12, 2025 |
| Real-world look at severe respiratory failure (ARDS) | — | Shanghai, Shanghai Municipality | Recruiting | Sep 10, 2025 |
| A kidney cancer prediction model to guide treatment decisions, including for patients with tumor thrombus | — | Beijing, Beijing Municipality | Recruiting | Aug 12, 2025 |
| AI model to help doctors predict patient outcomes | — | Wenzhou, Zhejiang and 1 other locations | Recruiting | Feb 26, 2025 |
| Observational study of lorlatinib for advanced ALK-positive lung cancer patients | — | Chengdu, Sichuan | Recruiting | Apr 12, 2024 |
All recruiting trials (7)
-
Real-world use of LC-OCT to help diagnose basal cell carcinoma
This study tests how well LC-OCT works in everyday dermatology practice to help diagnose basal cell carcinoma without always needing a biopsy.
-
Iruplinalkib for ALK-positive advanced lung adenocarcinoma after lorlatinib
We will try iruplinalkib in adults with advanced ALK-positive lung adenocarcinoma who progressed on or couldn't tolerate lorlatinib to see how well it works and how safe it is in routine care.
-
Real-world first-line atezolizumab for stage IV NSCLC with PD-L1 ≥50% in Türkiye
This project will see how well first-line atezolizumab works and how safe it is for adults with stage IV non-small cell lung cancer whose tumors have PD-L1 ≥50% and no targetable mutations in routine care in Türkiye.
-
Real-world look at severe respiratory failure (ARDS)
This project will collect real-world data on adults at high risk for ARDS to see which clinical factors predict worse outcomes.
-
A kidney cancer prediction model to guide treatment decisions, including for patients with tumor thrombus
This project will test whether a new prediction model can guide treatment choices to improve survival for adults with renal cell carcinoma, including those with venous tumor thrombus.
-
AI model to help doctors predict patient outcomes
This study is testing a new AI tool to see if it can help doctors better predict patient outcomes like diagnoses and hospital stays.
-
Observational study of lorlatinib for advanced ALK-positive lung cancer patients
This study looks at how well lorlatinib works and how safe it is for people with advanced ALK-positive lung cancer who are receiving treatment.
Related topics
Quick answers
How many Real World Study clinical trials are recruiting right now?
7, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 3 countries. The most sites are in China (5 trials), Turkey (Türkiye) (1 trial), Netherlands (1 trial). Each study page lists its sites and which ones are recruiting.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.